NRG Publications Committee. Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD

Transcription

1 NRG Publications Committee Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD

2 NRG Abstract and Manuscript Submissions 161 Manuscripts 105

3 Publications in High Impact Journals Published Impact Factor Total 2017 Citation NEJM Lancet Shipley WU, etal; NRG Oncology RTOG. RT +Antiandrogen Therapy in Recurrent Prostate Cancer Feb 2;376(5): Tewari KS, etal. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis (GOG240) Jul 27. pii:s (17) van den Bent MJ, etal CATNON EORTC glioma trial. Lancet Aug 8. pii: S (17) JAMA Coleman RL etal. Bevacizumab and paclitaxel-carboplatin and secondary cytoreduction in recurrent ovarian (NRG Oncology/GOG) 18(6): Lancet Oncology Lacas B, & MARCH Collab. Grp. Role of RT fractionation in H&Nca: meta-analysis. Lancet Oncol Sep;18(9): Brown PD, etal. Postop stereotactic radiosurgery vs whole brain RT for resected metastatic disease (NCCTG): 2017;18 (8): JCO JAMA Oncology JNCI Total 24

4 Publications Issues Lack of review of Pubs Policy Authorship inclusion confusion Author responsibilities Timely draft of publications Timely review by co-authors Timely signing of COI Minimum TWO step process for NIHMS submission Requests to submit to predatory publications

5 NIHMS Compliance

6 Publications Tab NRG Oncology Publications Policy and Guidelines Pubs Policy v NIH Manuscript Submission Requirements What Corresponding Authors Need to Know Need to Data Sharing Policy Data Sharing Policy v Presentation Templates PowerPoint Presentation Poster Oblong Poster Square Resources Tab NRGOncology.org Ancillary Projects Policy Ancillary Projects Application Form Data Sharing vs Ancillary Projects Requests Review Cycle NRG Staff Resources Central manuscript submission Help with NIHMS

7 NRG NCORP Principal Investigators Deborah Watkins Bruner, PhD Lawrence Wickerham, MD Joan Walker, MD

8 Cancer Care Delivery

9 Cancer Prevention and Control Study No Disease Site Description Date Activated Target Accrual Total Accrual CCOP/NCORP accrual (%) Target Monthly Accrual Expected Closure Date GOG 225 Ovary Diet and physical activity 6/18/ % 17 July 2018 RTOG 237 Cervix 278 Cervix CA IX, P16, markers & HPV in dx of AGC 2/9/ Japan 325 Korea 540 US 325 Japan 321 US 257 Korea <1% 11 before/after non radical surgery Physical fx & QOL 10/1/ <1% 5 Japan 3/2016 US ~4.5 years Korea ~8 months December 2020 NRG CC001 Brain Memantine and WBRT +/ HA CC003 Lung Seamless Ph II/III PCI vs. PCI with hippocampal sparing 7/13/ (16%) 9 Feb /7/ (II) 302 (III) (23%) 6 Ph II Closed on Oct 13 th CC004 Breast, GYN Ph II double blinded Bupropion 5/31/ (100%) 10* N/A

10 NRG Treatment Trials with PRO Endpoints 25/42 (60%) NRG Treatment Trials have PRO Endpoints PRO compliance remains an issue Compliance working group implementing strategies to address PRO/QOL chairs to monitor more closely and contact sites Protocol/Disease Site Webinars Working on report cards Audits will increase focus on compliance

11 NCORP RFA RFAs will likely be released in April or early May. There are changes to the PHS Human Subjects and Clinical Trial Information forms and NCORP is the first within the NCI clinical trials network to initiate these changes. Changes to the PHS form related to clinical trials will be Funding Opportunity Announcement specific We will have a minimum of 60 days after the release of the RFAs. Currently, we are estimating a due date in late summer. New funding for biobanking to be included CCD will have increased funding

12 Transitions and Thank You! David Alberts, MD, CPC David Cohn, MD, CCD